Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Melvin Helm

Neurology Fresno, CA Medical Doctor

NPI 1124076211 CMS profile 96834

1191 E Herndon Ave, Ste 102, Fresno, CA 93720

Open in the dashboard

General payments

$203,410

703 records reported · program years 2019–2021

Research payments

$12,825

Paid to them · 2 records reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$898,252 paid to institutions, not to them · program years 2019–2022

Through program year 2021, Melvin Helm of Fresno, CA is reported in the CMS Open Payments database as having received $203,410 across 703 general payments and $12,825 in research payments paid to them. Separately, studies naming them as principal investigator received $898,252 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $67,419 223
2021 Research $1,300 1
2020 General $76,992 244
2020 Research $11,525 1
2019 General $58,999 236

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melvin Helm
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Melvin Helm were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Melvin Helm Neurology median Middle half National median
2019 $58,999 $474 $118–$2,177 $163
2020 $76,992 $367 $82–$2,309 $114
2021 $67,419 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Allergan Inc. $51,388 128 payments
  2. Lilly USA, LLC $43,610 62 payments
  3. Teva Pharmaceuticals USA, Inc. $36,818 83 payments
  4. AbbVie, Inc. $24,862 67 payments
  5. Biohaven Pharmaceuticals, Inc. $22,815 46 payments
  6. Amgen Inc. $18,041 51 payments
  7. Lundbeck LLC $2,556 15 payments
  8. Novartis Pharmaceuticals Corporation $552 61 payments
  9. Sunovion Pharmaceuticals Inc. $300 36 payments
  10. UCB, Inc. $290 13 payments
  11. Other $2,177 141 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $180,000 111 payments
  2. Food and Beverage $11,246 560 payments
  3. Consulting Fee $5,901 6 payments
  4. Travel and Lodging $4,543 21 payments
  5. Honoraria $1,700 2 payments
  6. Education $19 3 payments
Products named General payments · program years 2019–2021
  1. UBRELVY Neuroscience $32,270 65 payments
  2. EMGALITY $28,127 46 payments
  3. UBRELVY Neuroscience $27,988 64 payments
  4. NURTEC ODT $22,815 46 payments
  5. Ajovy Central Nervous System $19,081 39 payments
  6. AIMOVIG $18,562 110 payments
  7. AJOVY Central Nervous System $17,737 44 payments
  8. REYVOW $12,165 15 payments
  9. BOTOX Neuroscience $9,063 14 payments
  10. BOTOX Neuroscience $6,220 5 payments
  11. Other $6,271 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2021
  1. Eli Lilly and Company $12,825 2 payments

Records

705 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record